ArticleOncotarget2017
A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- PDCD4: A critical regulator in leukemic signaling networks and its therapeutic potential.Molecular biology reports · 2025Review
- MLR Corresponds to the Functional Status of Monocytes in Chronic Lymphocytic Leukemia.International journal of inflammation · 2025Article
- Exosomal and intracellular miR-320b promotes lymphatic metastasis in esophageal squamous cell carcinoma.Molecular therapy oncolytics · 2021Article
- Long non-coding RNA LINC01018 inhibits the progression of acute myeloid leukemia by targeting miR-499a-5p to regulate PDCD4.Oncology letters · 2021Article
- miR-21-5p promotes cell proliferation by targeting BCL11B in Thp-1 cells.Oncology letters · 2021Article
- Integrated analysis of microRNA and transcription factors in the bone marrow of patients with acute monocytic leukemia.Oncology letters · 2021Article
- Downregulation of miR-142a Contributes to the Enhanced Anti-Apoptotic Ability of Murine Chronic Myelogenous Leukemia Cells.Frontiers in oncology · 2021Article
- LINC01128 resisted acute myeloid leukemia through regulating miR-4260/NR3C2.Cancer biology & therapy · 2020Article
- MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.Cancers · 2020Review
- Stat-3 signaling promotes cell proliferation and metastasis of gastric cancer through PDCD4 downregulation.The Kaohsiung journal of medical sciences · 2020Article
- Single‑cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction.Oncology reports · 2020Article
- DTL promotes cancer progression by PDCD4 ubiquitin-dependent degradation.Journal of experimental & clinical cancer research : CR · 2019Article
- Multiplexed single-cell RNA-seq via transient barcoding for simultaneous expression profiling of various drug perturbations.Science advances · 2019Article
- Non-coding RNAs in Natural Killer/T-Cell Lymphoma.Frontiers in oncology · 2019Review
- MicroRNAs in Autoimmunity and Hematological Malignancies.International journal of molecular sciences · 2018Review
- MicroRNA21 and the various types of myeloid leukemia.Cancer gene therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are regulators of several key patho-physiological processes, including cell cycle and apoptosis. Using microarray-based miRNA profiling in K562 cells, a model of chronic myeloid leukemia (CML), we found that the oncoprotein BCR-ABL1 regulates the expression of miR-21, an "onco-microRNA", found to be overexpressed in several cancers. This effect relies on the presence of two STAT binding sites on the promoter of miR-21, and on the phosphorylation status of STAT5, a transcription factor activated by the kinase activity of BCR-ABL1. Mir-21 regulates the expression of PDCD4 (programmed cell death protein 4), a tumor suppressor identified through a proteomics approach. The phosphoSTAT5 - miR-21 - PDCD4 pathway was active in CML primary CD34
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.